Fig 1: Puerarin disturbs F-actin ring formation via depressing Integrin-ß3-mediated Pyk2-Src-Cbl pathway (A) Representative blots of Pyk2-Src-Cbl signaling pathway related proteins were determined at day 4 under the treatment of puerarin for day 1 to day 4 in OCM (B–G) Band intensities were quantified and normalized relative to GAPDH (n ?= ?5) (H–I) mRNA expression of Integrin-ß3 and c-Src related to ß-actin under OCM with the treatment of puerarin for 2 or 4 days (n ?= ?5) (J) Inhibition curves of puerarin on Src kinase activity. Saracatinib (1000 ?nM) was a positive Src kinase inhibitor (n ?= ?5); NC: Negative control, cells treated with vehicle (0.1% DMSO) in the absent of OCM; The groups of C, PC, and different concentration of puerarin were induced by OCM. C: Control, cells treated with vehicle (0.1% DMSO); PC: Positive control, cells treated with 17-ß estradiol (E2, 0.01 ?µM), Puerarin (100–1000 ?µM): cells treated with different concentrations of puerarin (dissolved in DMSO). Data expressed are means ?± ?SD; *P ?< ?0.05, significantly different from the control group.